Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
First Affiliated Hospital of Zhejiang University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07396480CT.gov Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial | — | Recruiting | — | — | — |
NCT05583175CT.gov Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | — | Unknown | — | — | — |
NCT05115630CT.gov Off-the-shelf NK Cells + SCT for Myeloid Malignancies | — | Completed | — | — | — |
NCT04250051CT.gov Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02756572CT.gov Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms | — | Completed | — | — | — |
NCT01596699CT.gov Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation | — | Terminated | — | — | — |
NCT01366612CT.gov Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloid Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | First Affiliated Hospital of Zhejiang University | P3 | BB · 66 |
| Mitoxantrone | First Affiliated Hospital of Zhejiang University | P3 | BBB |
| Cytarabine | First Affiliated Hospital of Zhejiang University | P3 | BBB |
| Cladribine | University of Washington | P2 | BBB |
| Cyclophosphamide | Prelude Therapeutics | P3 | BB |
| Recombinant Human Granulocyte Colony-Stimulating Factor | University of Washington | P2 | BB |
| Venetoclax | First Affiliated Hospital of Zhejiang University | P3 | BB |
| Idarubicin | Northwestern University | P3 | BB |
| Nivestim | Franziska Wachter | P2 | BB |
+38 more in the Myeloid Neoplasm cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Myeloid Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-myeloid-neoplasm-68587
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →